.:: Yazd Biotechnology Incubator ::.

Wednesday, 30 Mordad 1387

Prophylactic Staphylococcus aureus subunit vaccine shows promising results

22 Dec 2006 - Intercell AG has been informed by its strategic partner Merck & Co., Inc. that a Phase I study of a recombinant subunit vaccine to prevent Staphylococcus aureus

Innogenetics extends its diagnostics product portfolio for Alzheimer's disease with new products

22 Dec 2006 - Innogenetics NV announced that Innogenetics has entered into a distribution agreement with Immuno-Biological Laboratories Co., Ltd. (IBL Japan). Innogenetics gains

Challenges and Opportunities in the Global Protein Therapeutics Market

22 Dec 2006 - The global protein therapeutics market was valued at US $57 billion in 2005 according to Arrowhead Publishers' new report The Global Protein Therapeutics Market - Market Dynamics and Pipeline Analysis. Biotechnology has

Enigma Diagnostics appoints Professor Christopher Lowe as non-executive director

22 Dec 2006 - Enigma Diagnostics, a life sciences company developing rapid molecular diagnostics systems, announced the appointment of Professor Christopher Lowe as Non-executive Director.

Organon's insomnia compound Org 50081 moves into phase III clinical trials

22 Dec 2006 - Organon, the human healthcare business unit of Akzo Nobel, has moved Org 50081, a Serotonin 2 blocker (S2B) for the treatment of insomnia, into Phase III clinical development.



	Prophylactic Staphylococcus aureus subunit vaccine shows promising results Innogenetics extends its diagnostics product portfolio for Alzheimer's disease with new products Challenges and Opportunities in the Global Protein Therapeutics Market Enigma Diagnostics appoints Professor Christopher Lowe as non-executive director Organon's insomnia compound Org 50081 moves into phase III clinical trials